Nsclc Non Small Cell Lung Cancer clinical trials

Explore recruiting nsclc non small cell lung cancer clinical trials.

Recruiting nsclc non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nsclc Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance therapy in ctDNA positive NSCL. The Cemited study.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Germany, Netherlands, Norway, Spain, Hungary, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091

Spain, Denmark, Czechia, Latvia, Italy, Poland +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Nsclc Non Small Cell Lung Cancer trials by city

Nsclc Non Small Cell Lung Cancer in Toronto Nsclc Non Small Cell Lung Cancer in Vancouver Nsclc Non Small Cell Lung Cancer in Montreal Nsclc Non Small Cell Lung Cancer in Calgary Nsclc Non Small Cell Lung Cancer in Edmonton Nsclc Non Small Cell Lung Cancer in Ottawa Nsclc Non Small Cell Lung Cancer in Winnipeg Nsclc Non Small Cell Lung Cancer in Quebec City Nsclc Non Small Cell Lung Cancer in Hamilton Nsclc Non Small Cell Lung Cancer in Kitchener Nsclc Non Small Cell Lung Cancer in London Nsclc Non Small Cell Lung Cancer in Halifax Nsclc Non Small Cell Lung Cancer in New York Nsclc Non Small Cell Lung Cancer in Los Angeles Nsclc Non Small Cell Lung Cancer in Chicago Nsclc Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease